uniQure (NASDAQ:QURE) Stock Price Down 9.5% – Time to Sell?

uniQure N.V. (NASDAQ:QURE) traded down 9.5% on Friday . The company traded as low as $20.72 and last traded at $20.2390. 1,507,503 shares changed hands during trading, a decline of 21% from the average session volume of 1,917,395 shares. The stock had previously closed at $22.37.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on uniQure, which may provide some analyst support for the stock. Read More.
• Positive Sentiment: Aggregate analyst coverage shows a consensus “Moderate Buy” on QURE, a signal that some sell‑side analysts still view upside. Read More.
• Neutral Sentiment: Profile/feature mentions (e.g., a Time piece listed in feeds) appear unrelated to the securities actions and are unlikely to move the stock materially. Read More.
• Negative Sentiment: Multiple law firms have filed or announced securities‑class actions and investor alerts against uniQure alleging violations of federal securities laws for the period Sept. 24, 2025–Oct. 31, 2025 — several firms (Schall, Rosen, Berger Montague, Kessler Topaz, DJS, Faruqi, Bernstein Liebhard, ClaimsFiler, etc.) are soliciting lead‑plaintiff applications and investigations. This wave of litigation increases legal risk, potential damages, and investor uncertainty. Read More. Read More. Read More.
• Negative Sentiment: At least one notice and media summary links the litigation to an alleged FDA approval delay and a roughly 49% prior stock decline; such factual allegations (if pursued) could prolong volatility, increase settlement risk, and weigh on investor sentiment. Read More.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. William Blair restated a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Barclays started coverage on uniQure in a research note on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price target for the company. Benchmark restated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company decreased their price objective on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Stock Performance

The firm’s 50 day moving average is $23.37 and its 200-day moving average is $29.13. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.67 and a beta of 0.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Large investors have recently bought and sold shares of the company. Private Trust Co. NA purchased a new position in shares of uniQure in the third quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its holdings in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 533 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its position in shares of uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 650 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.